We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

This study is currently recruiting participants.
Verified August 2017 by Helix BioPharma Corporation
Sponsor:
ClinicalTrials.gov Identifier:
NCT02309892
First Posted: December 5, 2014
Last Update Posted: August 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Theradex
Information provided by (Responsible Party):
Helix BioPharma Corporation
  Purpose
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous Non-Small Cell Lung Cancer.

Condition Intervention Phase
Non-Small Cell Lung Cancer Drug: L-DOS47 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination With Pemetrexed/Carboplatin in Patients With Stage IV (TNM M1a and M1b) Recurrent or Metastatic NSCL Lung Cancer

Resource links provided by NLM:


Further study details as provided by Helix BioPharma Corporation:

Primary Outcome Measures:
  • Number of patients with adverse events as a measure safety and tolerability of L-DOS47 in combination treatment with pemetrexed/carboplatin [ Time Frame: Participants will be followed for 12 weeks ]
    The AE reporting period starts on Cycle 1 Day 1 up to the last study visit.


Secondary Outcome Measures:
  • Objective response rate of patients receiving the combination treatment according to RECIST 1.1 [ Time Frame: Up to 12 weeks ]
    Objective tumor response will be assessed according to RECIST version 1.1 in patients who have completed at least 2 cycles of study treatment and who have at least 1 post-treatment disease assessment.

  • Number of patient receiving a sustained clinical benefit [ Time Frame: Up to 12 weeks ]
    Defined as the percentage of patients who have achieved complete response, partial response, and stable disease following combination treatment with L-DOS47 + pemetrexed/carboplatin.

  • Maximum observed plasma concentration (Cmax) of L-DOS47 after dosing in combination treatment with pemetrexed/carboplatin [ Time Frame: Up to 12 weeks ]
    Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patients dosed with L-DOS47

  • Time to maximum observed plasma concentration (Tmax) of L-DOS47 after dosing in combination treatment with pemetrexed/carboplatin [ Time Frame: Up to 12 weeks ]
    Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patients dosed with L-DOS47

  • Area under the concentration (AUC) vs time curve of L-DOS47 after dosing in combination treatment with pemetrexed/carboplatin [ Time Frame: Up to 12 weeks ]
    Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patients dosed with L-DOS47

  • Terminal elimination half-life of L-DOS47 after dosing in combination treatment with pemetrexed/carboplatin [ Time Frame: Up to 12 weeks ]
    Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patients dosed with L-DOS47

  • The presence of anti-L-DOS47 antibodies for patients dosed with L-DOS47 in combination treatment with pemetrexed/carboplatin [ Time Frame: Up to 12 weeks ]
    Serum samples will be collected and analyzed from all patients dosed with L-DOS47


Estimated Enrollment: 40
Study Start Date: April 2014
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pemetrexed and Carboplatin plus L-DOS47
Patients will be recruited into cohorts of L DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L DOS47 will be 0.59 µg/kg; further possible dose levels that may be assessed are 0.78, 1.04, 1.38 and 1.84 µg/kg. The standard of care doses of pemetrexed [500 mg/m2] and carboplatin [AUC6], respectively, to be administered in combination with L-DOS47, will remain constant across cohorts.
Drug: L-DOS47
A treatment cycle will be 21 days, with patients receiving L DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.

Detailed Description:
It is planned that patients will receive 4 cycles of combination treatment with L-DOS47 + pemetrexed/carboplatin. Patients who have not progressed following the 4 cycles of combination treatment and who have not experienced unacceptable toxicity will have the opportunity to continue to receive L-DOS47 treatment for as long as there is clinical benefit and it is well-tolerated, in the opinion of the Investigator, until disease progression. Patients who are unable to complete 4 cycles of L-DOS47 + pemetrexed/carboplatin combination treatment due to pemetrexed/carboplatin toxicity will have the opportunity to continue receiving L-DOS47 treatment following discontinuation of pemetrexed/carboplatin, for as long as there is clinical benefit and it is well-tolerated, in the opinion of the Investigator, until disease progression.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  1. Male or female patient ≥ 18 years of age
  2. Histologically or cytologically confirmed non-squamous NSCLC
  3. EGFR-mutation positive patients must have progressed on or had intolerance to an EGFR small molecule tyrosine kinase inhibitor
  4. Patients whose tumors harbor an anaplastic lymphoma kinase (ALK) translocation must have progressed on or had intolerance to an ALK inhibitor;
  5. No prior adjuvant chemotherapy within 1 year of the first treatment day if there is recurrent disease
  6. At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and minimum life expectancy of ≥ 3 months
  8. Adequate bone marrow, renal and liver function

Main Exclusion Criteria:

  1. Histologic evidence of predominantly squamous cell NSCLC
  2. Brain metastasis and/or leptomeningeal disease (known or suspected)
  3. Peripheral neuropathy > CTCAE grade 1
  4. Possibility of a curative local treatment (surgery and/or radiotherapy)
  5. Previous chemotherapy except adjuvant treatment with progression of disease documented ≥ 12 months after end of adjuvant treatment
  6. Having received treatment in another clinical study within the 30 days prior to commencing study treatment or having side effects of a prior study drug that are not recovered to grade ≤ 1 or baseline, except for alopecia
  7. Concurrent chronic systemic immunotherapy, chemotherapy or hormone therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02309892


Contacts
Contact: Steve Demas 905-841-2300 ext 282 sdemas@helixbiopharma.com

Locations
United States, Ohio
University Hospitals Case Medical Center Recruiting
Cleveland, Ohio, United States
United States, Texas
The University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States
Sponsors and Collaborators
Helix BioPharma Corporation
Theradex
  More Information

Additional Information:
Responsible Party: Helix BioPharma Corporation
ClinicalTrials.gov Identifier: NCT02309892     History of Changes
Other Study ID Numbers: LDOS001
First Submitted: April 9, 2013
First Posted: December 5, 2014
Last Update Posted: August 14, 2017
Last Verified: August 2017

Keywords provided by Helix BioPharma Corporation:
Non-Small Cell Lung Cancer
Neoplasms
Immunoconjugate
Tumor microenvironment alkalinization

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Carboplatin
Pemetrexed
Immunoconjugates
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors
Immunologic Factors
Physiological Effects of Drugs